SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/2B0AF896A3A3D0208F8A52DE8AB96706A8694E5C0DC8840B5E7BE5387761267E0DD9BD275FF46F7AE43AF001E12F2222>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/2B0AF896A3A3D0208F8A52DE8AB96706A8694E5C0DC8840B5E7BE5387761267E0DD9BD275FF46F7AE43AF001E12F2222
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/2B0AF896A3A3D0208F8A52DE8AB96706A8694E5C0DC8840B5E7BE5387761267E0DD9BD275FF46F7AE43AF001E12F2222
http://www.w3.org/2000/01/rdf-schema#comment
"EGFR mutations in esophageal carcinoma are rare but do exist and thus gefitinib could be included in esophageal cancer treatment regimens by selecting those patients who possess such mutations."
xsd:string
http://purl.uniprot.org/uniprot/#_104C39A1611F7150279477956C26291BB9A39A0D0A36FE8D3178EBB24A56DE3E9C0C9674D46E395C8EB79A1408BE3EC1
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/2B0AF896A3A3D0208F8A52DE8AB96706A8694E5C0DC8840B5E7BE5387761267E0DD9BD275FF46F7AE43AF001E12F2222
http://purl.uniprot.org/uniprot/L0R6G1
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/2B0AF896A3A3D0208F8A52DE8AB96706A8694E5C0DC8840B5E7BE5387761267E0DD9BD275FF46F7AE43AF001E12F2222
http://purl.uniprot.org/uniprot/#_L0R6G1-mappedCitation-17142003
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/2B0AF896A3A3D0208F8A52DE8AB96706A8694E5C0DC8840B5E7BE5387761267E0DD9BD275FF46F7AE43AF001E12F2222